Baylor Scott & White Charles A. Sammons Cancer Center – Dallas and Baylor Scott & White T. Boone Pickens Cancer Hospital make up one of the largest cancer treatment centers in the U.S. As a destination cancer center in immunotherapy and backed by the resources of Texas’ largest not-for-profit healthcare system, we offer innovative, comprehensive and personalized cancer care plans tailored to each patient’s unique needs. From highly specialized programs based on type of cancer to forward-thinking clinical trials to a holistic approach to healing, we are with our patients along every step of their journey no matter how challenging the road becomes.
NKT Cells Co-Expressing GD2-CAR, IL-15 Can Induce Complete Remissions in Pediatric Neuroblastoma
May 15th 2021Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.
Dr. Kelly on the Outlook of ALK-Positive NSCLC
May 14th 2019Ronan J. Kelly, MD, MBA, chief of oncology for the 10 Baylor Scott & White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the outlook of patients with ALK-positive non–small cell lung cancer (NSCLC).
Dr. Kelly Discusses the Treatment of Patients With ALK+ NSCLC
May 7th 2019Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.
Chemoimmunotherapy Combos Solidified as Frontline Standard in Nonsquamous NSCLC
May 3rd 2019The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.
Dr. Nadler Discusses the IMpower131 Study in Squamous NSCLC
May 2nd 2019Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the IMpower131 study in squamous metastatic non–small cell lung cancer.
Dr. Kelly on the Benefit of Immunotherapy in Stage III NSCLC
May 2nd 2019Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott & White Health's North Texas Cancer Centers and director of oncology at the Baylor Charles A. Sammons Cancer Center on the campus of Baylor University Medical Center, discusses the benefit of immunotherapy in patients with stage III non–small cell lung cancer (NSCLC).
Dr. Konduri Discusses Promise of NGS Testing in NSCLC
May 1st 2019Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses the promise of next-generation sequencing testing in patients with non–small cell lung cancer.
Dr. Konduri on Treatment Options for Patients With EGFR-Mutant NSCLC
April 24th 2019Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses treatment options available for patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Dr. Konduri on Sequencing Therapy in EGFR+ NSCLC
April 18th 2019Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, on the campus of Baylor University Medical Center, discusses sequencing therapy in patients with EGFR-positive non–small cell lung cancer.
Dr. Paulson Discusses Unmet Needs in the Treatment of NETs
September 27th 2018Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses unmet needs in the treatment of patients with neuroendocrine tumors.
Dr. Paulson Discusses the Current Treatment for NETs
September 5th 2018Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses the current treatment of patients with neuroendocrine tumors.
Expert Discusses Finding the Optimal Treatment Strategy in CRC
A. David McCollum, MD, discusses the need for greater use of molecular profiling, the importance of tumor sidedness when selecting a treatment regimen, and the value of maintenance therapy in patients with metastatic disease.